LUNG CANCER

During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.

In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.

Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.

During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the Lung-MAP nonmatched substudy S1800A for patients with non–small cell lung cancer who were previously treated with immune checkpoint inhibitors and develop resistance.

During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.

A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.

At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.

According to Conor E. Steuer, MD, patritumab deruxtecan showed promising clinical activity in heavily pretreated patients with advanced non–small cell lung cancer with or without identified variant genomic alterations.

Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.

Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.

Three-year follow-up of the CheckMate 9LA trial shows continued survival benefit to nivolumab/ipilimumab plus 2 cycles of chemotherapy in patients with metastatic non–small cell lung cancer.

The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.

Karen L. Reckamp, MD, explains the need for more treatment options for patients with non–small cell lung cancer who have been previously treated with immune checkpoint inhibitors and develop resistance.

During a Targeted Oncology case-based roundtable event, Mark A. Socinski, MD, discussed the results of clinical trials supporting the use of targeted agents in patients with late-stage lung cancers.

During a live virtual event, Aaron E. Lisberg, MD, discussed the value of molecular testing in patients recently diagnosed with early-stage lung cancer.

During a live virtual event, Ravi Salgia, MD, PhD, discussed treatment considerations for a patient with non–small cell lung cancer with a brain metastasis.

GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.

Findings from a retrospective real world study conducted in patients with EGFR-mutated, stage IV non–small cell lung cancer from 4 Latin American countries showed a 66% frequency rate in molecular testing and a frequency of EGFR mutations of 22% overall.

Martin Dietrich, MD, PhD, discusses the study design and results of the CheckMate 9LA trial of ipilimumab and nivolumab for patients with non–small cell lung cancer.

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

A collaboration between Merck and Athenex, Inc. has been announced to evaluate oraxol plus pembrolizumab in certain patients with non-small cell lung cancer.

Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.